{"mtb_report":
{
  "patient": {
    "id": "9",
    "age": null,
    "sex": "M",
    "birth_date": null
  },
  "diagnosis": {
    "primary_diagnosis": null,
    "stage": null,
    "histology": null,
    "icd_o_code": null
  },
  "variants": [
    {
      "gene": "JAK2",
      "cdna_change": null,
      "protein_change": "V617F",
      "classification": null,
      "vaf": 1.0,
      "raw_text": null,
      "gene_code": {
        "code": "HGNC:6192",
        "system": "http://www.genenames.org",
        "name": "Janus Kinase 2",
        "chromosome": "9",
        "cancer_types": [
          "Myeloproliferative neoplasms"
        ],
        "actionable": true
      }
    },
    {
      "gene": "JAK2",
      "cdna_change": null,
      "protein_change": "V617F è tipica della policitemia vera e di altre sindromi mieloproliferative",
      "classification": null,
      "vaf": null,
      "raw_text": null,
      "gene_code": {
        "code": "HGNC:6192",
        "system": "http://www.genenames.org",
        "name": "Janus Kinase 2",
        "chromosome": "9",
        "cancer_types": [
          "Myeloproliferative neoplasms"
        ],
        "actionable": true
      }
    },
    {
      "gene": "EGFR",
      "cdna_change": null,
      "protein_change": "exon 19 deletion",
      "classification": "Pathogenic",
      "vaf": null,
      "raw_text": null,
      "gene_code": {
        "code": "HGNC:3236",
        "system": "http://www.genenames.org",
        "name": "Epidermal Growth Factor Receptor",
        "chromosome": "7",
        "cancer_types": [
          "NSCLC",
          "Glioblastoma",
          "Colorectal"
        ],
        "actionable": true
      }
    }
  ],
  "recommendations": [
    {
      "drug": "amivantamab",
      "gene_target": "EGFR",
      "evidence_level": "FDA Approved",
      "clinical_trial": null,
      "rationale": null,
      "drug_code": {
        "code": "2569455",
        "system": "RxNorm",
        "display": "amivantamab",
        "target": [
          "EGFR"
        ],
        "indication": "EGFR exon 20 insertion NSCLC",
        "evidence_level": "FDA Approved"
      }
    }
  ],
  "tmb": null,
  "ngs_method": "possiamo identificare la specifica alterazione genica, ma dal punto di vista biologico tutte le delezioni (e delins) dell’esone 19 condividono il medesimo significato e determinano sensibilità agli inibitori tirosinchinasici.",
  "report_date": null,
  "quality_metrics": {
    "total_fields": 15,
    "filled_fields": 2,
    "completeness_pct": 13.3,
    "variants_found": 3,
    "variants_with_vaf": 1,
    "variants_classified": 1,
    "variants_with_gene_code": 3,
    "drugs_identified": 1,
    "drugs_mapped": 1,
    "diagnosis_mapped": false,
    "patient_complete": false,
    "warnings": [
      "Diagnosis not mapped to ICD-O",
      "Patient information incomplete",
      "TMB not found"
    ]
  }
}}
